The research team at NDSS is excited to share that we will be hosting an Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting with the U.S. Food and Drug Administration (FDA) in June to discuss Down Syndrome-associated Alzheimer's Disease (DS-AD). The EL-PFDD meeting will give the FDA and other key stakeholders the opportunity to hear directly from patients, their families, caregivers, and patient advocates specifically about the symptoms of DS-AD, the impacts on daily lives, patient experiences with current available treatments, and hopes for future therapies.
Information Webinar
Join us for a FREE community webinar to learn about the upcoming EL-PFDD meeting on DS-AD on Monday, April 6, 2026, at 3 PM ET. This session will provide an overview of the EL-PFDD meeting goals, explain how patient and caregiver experiences help inform drug development and regulatory decision-making, and share ways you can participate and make your voice heard.